Lucid Diagnostics (LUCD) risk factors, FY2024 10-K

Other

1. 01Risks Associated with Our Financial Condition
2. 02Risks Associated with Our Business
3. 03Risks Associated with Healthcare Regulation, Billing and Reimbursement, and Product Safety and Effectiveness
4. 04Risks Associated with Our Intellectual Property and Technology Infrastructure
5. 05Risks Associated with Our Relationship with PAVmed
6. 06Risks Associated with Ownership of Our Common Stock
7. 07We have incurred operating losses since our inception and may not be able to achieve profitability
8. 08We have concluded there is substantial doubt of our ability to continue as a going concern and our independent registered public accounting firm’s report on our financial statements contains an explanatory paragraph describing our ability to continue as a going concern
9. 09We expect to need additional capital funding, which may be compounded by our obligations to our parent company, PAVmed, which requires its own additional capital funding
10. 10Our quarterly operating results could be subject to significant fluctuation, which could increase the volatility of our stock price and cause losses to our stockholders
11. 11We may be required to repay or redeem at maturity in 2029 (or sooner, upon the occurrence of certain change of control transactions or an event of default), or to pay interest on, the 2024 Convertible Notes or any future permitted indebtedness incurred by us or our subsidiaries, in cash
12. 12The debt service requirements of any other permitted indebtedness we incur or issue in the future, as well as the restrictive covenants contained in the governing documents for any such indebtedness, could intensify these risks
13. 13Since we have a limited operating history, and have not generated any significant revenues to date, you will have little basis upon which to evaluate our ability to achieve our business objective
14. 14The markets in which we operate are attractive and other companies or institutions may develop and market novel or improved technologies, which may make the EsoGuard or EsoCheck technologies less competitive or obsolete
15. 15We expect to derive substantially all of our revenues from the EsoGuard and EsoCheck products
16. 16We are highly dependent on our license agreement with CWRU, the termination of which would prevent us from commercializing our products, and which imposes significant obligations on us
17. 17Our products may never achieve market acceptance
18. 18The sizes of the markets for our current and future products have not been established with precision, and may be smaller than we estimate
19. 19Recommendations in published clinical practice guidelines issued by various organizations, including professional societies and federal agencies may significantly affect payors’ willingness to cover, and physicians’ willingness to prescribe, our products and services
20. 20We or our third-party manufacturers may not have the manufacturing and processing capacity to meet the production requirements of consumer demand or clinical testing in a timely manner
21. 21The manufacturing processes for our products have not yet been tested at commercial levels, and it may not be possible to manufacture or process these materials in a cost-effective manner
22. 22Our results of operations can be adversely affected by labor shortages, turnover, and labor cost increases
23. 23Additionally, the operations of our vendors and partners could also suffer from labor shortages, turnover, and labor cost increases which could result in supply chain disruptions and increases in the costs of the products and services we purchase, each of which could adversely affect our operations
24. 24Our ability to be successful will be totally dependent upon the efforts of our key personnel
25. 25Our officers and directors have fiduciary obligations to other companies and, accordingly, may have conflicts of interest in determining to which entity a particular business opportunity should be presented
26. 26Our business may suffer if we are unable to manage our growth
27. 27Our business, financial condition and results of operations could be adversely affected by the political and economic conditions of the U.S. and the other countries in which we conduct business
28. 28We may engage in acquisitions that are not successful and which could disrupt our business, cause dilution to our stockholders and reduce our financial resources
29. 29Adverse results in material litigation matters could have a material adverse effect upon our business
30. 30Despite our initiative to establish a robust cash-pay program, successful commercialization of our EsoGuard test and EsoCheck device, and of any other product or service we develop, license or acquire depends, in large part, on the availability of adequate reimbursement from private or governmental third-party payors
31. 31Category of IVD Stage 1 Stage 2 Stage 3 Stages 4 & 5 (Premarket Review)
32. 32Securing FDA approval of EsoGuard as an IVD device, separately or as a combined product with EsoCheck, is a complex process requiring substantial time, commitment of resources and expense without any assurance that FDA will grant such approval
33. 33Failure to obtain regulatory approvals in foreign jurisdictions will prevent us from marketing our products internationally
34. 34Modifications to our cleared or approved products may require new clearances or premarket approvals, or may require us to cease marketing or recall the modified products until clearances are obtained
35. 35The results of our clinical trials may not support our product candidate claims or may result in the discovery of adverse side effects
36. 36Our principal ongoing clinical trials are those that relate to EsoGuard. For a summary of the status and certain information concerning the results of those trials, please see above under “Background and Overview—Clinical Utility and Clinical Trials”
37. 37EsoCheck and any other products we develop that receive regulatory clearance or approval will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and subject us to penalties if we fail to comply with applicable regulatory requirements
38. 38If we are found to be promoting the use of our devices for unapproved or “off-label” uses or engaging in other noncompliant activities, we may be subject to recalls, seizures, fines, penalties, injunctions, adverse publicity, prosecution, or other adverse actions, resulting in damage to our reputation and business
39. 39The regulations that govern pricing and reimbursement for new products vary widely from country to country, and may adversely affect the pricing, coverage and reimbursement rates of our products in other countries
40. 40Due to billing complexities in the diagnostic and laboratory service industry, we may not be able to collect payment for the EsoGuard tests we perform
41. 41Healthcare reform measures, including those targeting Medicare or Medicaid, could hinder or prevent our products’ commercial success
42. 42Our medical products may in the future be subject to product recalls that could harm our reputation, business, and financial results
43. 43If our medical products cause or contribute to a death or a serious injury, or malfunction in certain ways, we will be subject to medical device reporting regulations, which can result in voluntary corrective actions or agency enforcement actions
44. 44Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of our products
45. 45Compliance with the HIPAA security, privacy and breach notification regulations may increase our costs
46. 46We may not be able to protect or enforce the intellectual property rights for the technology used in, or expected to be used in, our products, which could impair our competitive position
47. 47We also rely on the use of registered and common law trademarks with respect to the brand names of some of our products. Common law trademarks provide less protection than registered trademarks
48. 48We may be subject to intellectual property infringement claims by third parties which could be costly to defend, divert management’s attention and resources, and may result in liability
49. 49Competitors may violate the intellectual property rights for the technology used in, or expected to be used in, our products, and we may bring litigation to protect and enforce our intellectual property rights, which may result in substantial expense and may divert our attention from implementing our business strategy
50. 50Failure in our information technology systems could significantly disrupt our operations and our research and development efforts, which could adversely impact our revenues, as well as our research, development and commercialization efforts
51. 51Our internal computer systems, or those used by our third-party research institution collaborators, vendors or other contractors or consultants, may suffer security breaches
52. 52PAVmed holds more voting stock than any of our other shareholders and thus it (or any successor to its stake in the Company), may have significant influence over certain actions requiring a stockholder vote
53. 53As a result of the exercise by the holder of PAVmed’s convertible debt and preferred stock of its rights under the agreements governing those instruments, such holder could acquire voting control of the Company
54. 54Certain conflicts of interest may arise between us and our affiliated companies, including PAVmed, and in some cases we have waived certain rights with respect thereto
55. 55Any disputes that arise between us and PAVmed with respect to our past and ongoing relationships could harm our business operations
56. 56If securities or industry analysts do not publish research, or publish inaccurate or unfavorable research, about our business, our stock price and trading volume could decline
57. 57Nasdaq may in the future delist our common stock, which could limit investors’ ability to make transactions in our securities and subject us to additional trading restrictions
58. 58Our stock price may be volatile, and holders of our common stock could incur substantial losses
59. 59We do not intend to pay any dividends on our common stock at this time
60. 60We are obligated to pay dividends in shares of our common stock to the holders of shares of our Series B Preferred Stock and Series B-1 Preferred Stock, which stock dividends will dilute our existing shareholders
61. 61We incur significant costs as a result of operating as a public company, and our management will be required to devote substantial time to compliance initiatives
62. 62If we fail to establish and maintain proper and effective internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our common stock could decline significantly
63. 63We are subject to evolving corporate governance and public disclosure expectations and regulations that impact compliance costs and risks of noncompliance
64. 64We are an “emerging growth company,” and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our common stock less attractive to investors
65. 65Provisions in our corporate charter documents and under Delaware law could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our current management